title: Systemic inflammation in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention.
abstract: OBJECTIVE
  Systemic inflammation plays an important role in both chronic obstructive pulmonary disease (COPD) and coronary artery disease (CAD). The purpose of the present study was to assess the association of high-sensitivity C-reactive protein (hs-CRP), a biomarker of systemic inflammation, with in-hospital outcomes in patients with COPD undergoing percutaneous coronary intervention (PCI).
  
  
  METHODS
  A total of 378 patients with COPD who were treated with PCI from January 2007 through January 2012, were divided into two groups according to hs-CRP level at admission. Demographics, clinical, angiographic data and in-hospital outcomes were compared.
  
  
  RESULTS
  Patients with elevated hs-CRP (≥3 mg/L) were more likely to be female and current smokers, had more severe airflow limitation, more hypertension, diabetes and cardiac dysfunction and had increased incidence of three-vessel disease and more type C lesions. Subjects with elevated hs-CRP were also less likely to have been prescribed with statins and B-blockers, perhaps. Rate of in-hospital composite major adverse cardiovascular events (MACEs) was higher (15.5% vs. 8.2%, P = 0.041) and hospital stay was longer (8.2 ± 2.0 vs. 7.5 ± 1.7 days, P < 0. 001) in patients with elevated hs-CRP. A combined analysis of MACE on the basis of airflow limitation and hs-CRP showed an exaggerated hazard ratio in the presence of both severe airflow limitation and elevated hs-CRP. In a multivariate analysis, elevated periprocedural hs-CRP was independently related with MACEs and hospital stay.
  
  
  CONCLUSIONS
  Elevated periprocedural hs-CRP is independently and additively related with increased incidence of in-hospital adverse outcomes in COPD patients undergoing PCI.
authors.affiliation: Pulmonary and Critical Care Department, Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, China.
authors.forename: Xiao Lei
authors.initials: XL
authors.lastname: Zhang
authors.forename: Yong Hui
authors.initials: YH
authors.lastname: Chi
authors.forename: Le Feng
authors.initials: le F
authors.lastname: Wang
authors.forename: Hong Shi
authors.initials: HS
authors.lastname: Wang
authors.forename: Xiang Min
authors.initials: XM
authors.lastname: Lin
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D003324:Coronary Artery Disease / Q000097:blood* / Q000401:mortality / Q000628:therapy*; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D015994:Incidence; D007249:Inflammation / Q000097:blood* / Q000175:diagnosis* / Q000453:epidemiology; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood* / Q000453:epidemiology; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein
keywords: chronic obstructive pulmonary disease; coronary artery disease; inflammation; percutaneous coronary intervention